Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genetic Signatures Ltd. ( (AU:GSS) ) has provided an update.
Genetic Signatures Ltd reported a significant increase in quarterly sales, driven by higher respiratory testing rates in Australia and the implementation of their EasyScreen Enteric Detection Kits in the UK. The company is advancing its US market entry with the EasyScreen Gastrointestinal Parasite Detection Kit, having completed test validations at several sites. Despite longer-than-expected sales cycles in the US, the company remains optimistic about future sales following FDA clearance. The company maintains a strong cash position, supported by a substantial R&D tax incentive, allowing it to continue its expansion and innovation efforts.
More about Genetic Signatures Ltd.
Genetic Signatures Ltd operates in the biotechnology sector, focusing on molecular diagnostics. The company’s primary products include the 3base technology platform and EasyScreen detection kits, which are used for infection control and pathogen detection. The company is strategically expanding its market presence, particularly in the US, following regulatory approvals.
YTD Price Performance: -1.59%
Average Trading Volume: 88,800
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$143.1M
For detailed information about GSS stock, go to TipRanks’ Stock Analysis page.
